Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics' stock has experienced several events over the past six months. The stock showed a 9.26% increase over the last six months as of February 8, 2026. The company announced its Q3 2025 earnings, reporting an EPS of -$0.47 and revenue of $11.15 million, exceeding analysts' expectations. HC Wainwright & Co. maintained a "Buy" recommendation for VYGR on November 12, 2025. The stock saw an 11.6% increase on October 9, 2025. Voyager Therapeutics reported its Q2 2025 earnings, which showed a loss and lagged revenue estimates. The company launched a new gene therapy program targeting APOE for Alzheimer's disease treatment on July 16, 2025. The stock was up 24% on June 2, 2025. Voyager Therapeutics published data on ALPL's role in AAV transport across the Blood-Brain Barrier on May 15, 2025. The company reported Q1 2025 losses and revenue that lagged estimates. An insider sale by the Chief Medical Officer occurred on April 4, 2025. The stock has experienced a decline of -5.19% compared to the previous week, an -8.21% fall over the last month, and a -36.33% decrease over the last year, as of February 3, 2026. The share price on February 3, 2026, was $3.91, representing a 29.29% decline from February 4, 2025.

As a clinical-stage biotechnology company, Voyager Therapeutics does not have commercial products and therefore does not experience traditional demand seasonality. Its revenue is primarily generated through licensing its gene therapy platforms and providing research and development services, influenced by upfront payments, R&D reimbursements, and milestone payments.

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases using human genetics. The company's pipeline includes programs such as VY7523 for Alzheimer's disease, VY1706 for Alzheimer's disease, SOD1 silencing gene therapy for ALS, vectorized anti-amyloid antibody for Alzheimer's disease, VY-FXN01 for Friedreich's ataxia, GBA1 gene replacement program for Parkinson's disease, and APOE gene therapy program for Alzheimer's disease. Voyager utilizes platforms like TRACER™ and Voyager NeuroShuttle™ and has collaborations with partners including Alexion, AstraZeneca, Novartis, and Neurocrine Biosciences.

Voyager Therapeutics, Inc. is headquartered in Lexington, Massachusetts, and was originally founded in Cambridge, Massachusetts. Its operations are primarily focused on research and development.

Voyager Therapeutics maintains a generally positive brand reputation, reflected by a "Moderate Buy" consensus rating from analysts. The company has made progress in its wholly-owned programs targeting tau for Alzheimer's disease and in partnered IV gene therapy programs, generating approximately $80 million in non-dilutive funding in 2024. The company's strong cash position is expected to provide operational runway into mid-2027, and potentially into 2028. The proprietary TRACER™ AAV capsid discovery platform and the Voyager NeuroShuttle™ non-viral delivery platform are seen as strategic advantages. A collaboration with Transition Bio to develop small molecules for ALS and FTD targeting TDP-43 further enhances its reputation. Novartis discontinued two discovery-stage programs, and the company reported a widened net loss in Q3 2025 due to lower collaboration revenue.

Voyager Therapeutics, Inc. has a diverse ownership structure, with 237 institutional owners holding 34,207,786 shares, representing approximately 55.09% of the shares. Major institutional shareholders include BlackRock, Inc., Armistice Capital, Llc, and Vanguard Group Inc. Individual investors represent the largest shareholder group, holding 26% of the company's shares. Hedge funds controlled 19% of shares. Insider ownership is relatively low, at 0.88%. Notable individual shareholders include Third Rock Ventures, LLC, EcoR1 Capital, LLC, and Neurocrine Biosciences, Inc.